Sonoco Products Company Common Stock (SON)

FairStock Score: 82/100 — HIGH CONVICTION

Key Financials

Strengths

• Generates $895 million in annual free cash flow (18.3% yield on market cap)
• High return on equity of 20.1% demonstrating efficient capital deployment
• Revenue growth of 379.8% demonstrates strong top-line momentum
• Attractive 4.5% dividend yield providing steady income returns
• FairStock composite score of 82/100 places it in the top tier across value, quality, and momentum factors

Concerns

• Altman Z-Score of 1.0 places it in the financial distress zone—elevated bankruptcy risk

AI Analysis

Sonoco Products Company Common Stock is a small-cap consumer cyclical company valued at $4.9 billion. The business generates $7.5 billion in annual revenue with a 0.9% net margin and $895 million in free cash flow. From a quality standpoint, Sonoco shows solid Piotroski F-Score of 6/9 and distressed Altman Z-Score of 1.0 warrants caution. On valuation, the stock is deeply undervalued on a P/E basis at 8.1x, with offers a 30% margin of safety vs Graham Number of $71. Growth dynamics show revenue growing at 379.8% and profit growth of 873.4%. The 4.5% dividend yield adds an income component for patient holders. Our composite FairStock Score of 82/100 reflects strong fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Sonoco's 380% revenue growth trajectory could accelerate as it captures additional market share in the consumer cyclical sector. With $895 million in annual free cash flow (18.3% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the consumer cyclical space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer